Bringing new concepts of functionalised nanoparticles for targeted delivery, SMi’s 7th annual RNA Therapeutics conference will feature a mix of case study-led presentations, panel debates, interactive workshops and keynote addresses tailored for an audience of professionals and research scientists looking to develop and commercialise novel RNA therapeutics and delivery systems.With a focus on messenger RNA-based Therapeutics and anti-sense oligonucleotide-based drugs, the agenda will hone in on major developments and tackle the challenge of transporting RNA to target sites outside the liver and optimise bioavailability and kinetics.Join us next February to expand your scientific horizons on topics such as ophthalmology injury, emerging concepts in delivery systems, oligonucleotides, aptamer-conjugates, messenger RNA therapeutics, plus much more!Reasons to Attend:Learn new Pre-clinical and clinical developments with antisense oligonucleotide based deliveryRationalise the design criteria of multifunctional nanoparticle carriersGain new insight of optimising mRNA therapeutics and delivery methodsUnderstand industry hurdles of targeted delivery beyond the liverDiscover new avenues in gene- based therapies Key Speakers Include:Ryszard Kole, Distinguished Scientist, Sarepta TherapeuticsNagy Habib, Professor of Surgery, Chairman & Co-founder Imperial College London, MiNA TherapeuticsPunit Seth, Executive Director, Isis PharmaceuticalsMustafa Diken, Deputy Vice President, Immunotherapies and Preclinical Research, BioNTech AGChristian Schetter, Chief Executive Office and Managing Director, Rigontech GmbHCristianne Rijcken, CSO, Cristal TherapeuticsHeinrich Haas, Vice President RNA Formulation & Drug Delivery, BioNTech AGBrian Kelly, Associate, Covington & Burling LLP